Volume 35, Issue 1, March 2024

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(1):78-85
Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature
Authors Information

1Memorial Sloan Kettering Cancer Centre, Integrative Medicine Service, New York City, New York, USA

2 Tishreen University, Faculty of Medicine, Latakia, Syria

3 American University of Beirut, Department of Internal Medicine, Division of Rheumatology, Beirut, Lebanon

S El Iskandarani, M Khasho, M Merashli


Eosinophilic fasciitis (EF) is a rare connective-tissue disorder that is characterised by subacute onset of erythema, oedema, and induration of the skin and soft tissues of the limbs and trunk. Although several triggers have been hypothesised to be associated with EF, the aetiology of eosinophilic fasciitis (EF) is still unclear, and several treatment regimens have been proposed to treat this disease. In this article, we report a case of a 72-year-old gentleman with multiple comorbidities who presented to the clinic for diffuse skin thickening present on his forearms, thighs, legs bilaterally, and over the pelvis. The patient was diagnosed with EF and failed multiple treatment regimens including prednisone, methotrexate, rituximab, but finally responded and was maintained on tocilizumab. In this article, we will review the current understanding of EF, diagnostic approach, popular treatments and review other cases of EF in which tocilizumab was used.

Cite this article as: El Iskandarani S, Khasho M, Merashli M. Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature. Mediterr J Rheumatol 2023;34(1):78-85.

Article Submitted: 25 Jul 2022; Revised Form: 21 Oct 2022; Article Accepted: 25 Oct 2022; Available Online: 31 Mar 2023



This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).